TD Asset Management Inc Grows Position in Corcept Therapeutics Incorporated $CORT

TD Asset Management Inc increased its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 16.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 956,136 shares of the biotechnology company’s stock after acquiring an additional 136,254 shares during the quarter. TD Asset Management Inc owned about 0.91% of Corcept Therapeutics worth $79,464,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Clearstead Advisors LLC boosted its holdings in shares of Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares during the last quarter. Golden State Wealth Management LLC bought a new stake in shares of Corcept Therapeutics in the second quarter worth about $28,000. Huntington National Bank lifted its position in shares of Corcept Therapeutics by 54.0% in the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock worth $35,000 after buying an additional 168 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in Corcept Therapeutics by 598.5% during the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 395 shares during the last quarter. Finally, Employees Retirement System of Texas purchased a new position in Corcept Therapeutics during the 2nd quarter valued at approximately $52,000. 93.61% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on CORT shares. HC Wainwright decreased their price objective on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective for the company. in a research note on Wednesday, December 31st. Finally, UBS Group began coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $77.17.

Insiders Place Their Bets

In related news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00. Following the completion of the transaction, the insider owned 1,235 shares in the company, valued at $50,474.45. The trade was a 94.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joseph K. Belanoff sold 40,000 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.77, for a total value of $3,190,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,701,370 shares in the company, valued at $215,488,284.90. This trade represents a 1.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 125,000 shares of company stock worth $8,301,450 over the last three months. 20.80% of the stock is currently owned by corporate insiders.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Management reiterated a large 2026 revenue opportunity — $900M–$1B — as relacorilant’s oncology approval approaches, supporting upside if approval and commercial traction materialize. Article Title
• Neutral Sentiment: Analyst note: HC Wainwright trimmed a long‑term FY2030 EPS forecast (from $7.74 to $7.19) but maintained a Buy rating and $67 target, signaling continued analyst confidence in the longer‑term story despite near‑term misses.
• Negative Sentiment: Q4 results missed consensus — EPS and revenue came in below expectations (Q4 EPS ~$0.20; revenue ~$202M vs. higher estimates), prompting investor concern about growth momentum and guidance. Article Title
• Negative Sentiment: Multiple law firms have announced securities‑fraud class‑action filings and are soliciting lead‑plaintiff applicants (class period cited Oct 31, 2024–Dec 30, 2025); a wave of litigation notices increases legal and reputational risk and may pressure the stock. Representative alerts include Hagens Berman and Pomerantz. Article Title Article Title

Corcept Therapeutics Stock Down 1.2%

NASDAQ CORT opened at $35.78 on Friday. The company has a quick ratio of 3.07, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $45.37 and a two-hundred day moving average of $66.02. The firm has a market capitalization of $3.81 billion, a price-to-earnings ratio of 43.63 and a beta of 0.25. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same quarter last year, the business posted $0.26 EPS. Corcept Therapeutics’s revenue was up 11.1% compared to the same quarter last year. On average, analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.